The SARS-CoV-2 2019 pandemic has created challenges to managing the post-infectious autoimmune consequences of a disease that leads to the high case fatality in adults and children. The spectrum of agents available to modulate and suppress the immune system in combination with other appropriate antiviral antibiotics and life support measures is reviewed. All of the agents envisioned to treat Covid-19 disorders, including a newly recognized pediatric multi-system inflammatory syndrome, impact post-infectious mechanisms in keeping with the multiplier effect of infection, immunity and inflammation known as I-Cubed (I3).
Younger, David S., "Post-Infectious Sequela of SARS-CoV-2 Infection in Adults and Children: An Overview of Available Agents and Clinical Responsiveness" (2020). CUNY Academic Works.